These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25501463)

  • 1. Health literacy in patients dealing with gout: a qualitative study.
    van Onna M; Hinsenveld E; de Vries H; Boonen A
    Clin Rheumatol; 2015 Sep; 34(9):1599-603. PubMed ID: 25501463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A joint effort over a period of time: factors affecting use of urate-lowering therapy for long-term treatment of gout.
    Richardson JC; Liddle J; Mallen CD; Roddy E; Hider S; Prinjha S; Ziebland S
    BMC Musculoskelet Disord; 2016 Jun; 17():249. PubMed ID: 27267878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implication of nurse intervention on engagement with urate-lowering drugs: A qualitative study of participants in a RCT of nurse led care.
    Latif ZP; Nakafero G; Jenkins W; Doherty M; Abhishek A
    Joint Bone Spine; 2019 May; 86(3):357-362. PubMed ID: 30394337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study.
    Singh JA
    Arthritis Res Ther; 2014 Mar; 16(2):R82. PubMed ID: 24678765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
    Corbett EJM; Pentony P; McGill NW
    Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Casebook consults: improving outcomes in gout (multimedia activity).
    Doghramji PP; Mandell BF; Pope RS
    Am J Med; 2012 Aug; 125(8):S1. PubMed ID: 22840678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A qualitative study to explore health professionals' experience of treating gout: understanding perceived barriers to effective gout management.
    Humphrey C; Hulme R; Dalbeth N; Gow P; Arroll B; Lindsay K
    J Prim Health Care; 2016 Jun; 8(2):149-56. PubMed ID: 27477557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication adherence among patients with gout: A systematic review and meta-analysis.
    Scheepers LEJM; van Onna M; Stehouwer CDA; Singh JA; Arts ICW; Boonen A
    Semin Arthritis Rheum; 2018 Apr; 47(5):689-702. PubMed ID: 29198878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
    Hill EM; Sky K; Sit M; Collamer A; Higgs J
    J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
    Rashid N; Coburn BW; Wu YL; Cheetham TC; Curtis JR; Saag KG; Mikuls TR
    J Rheumatol; 2015 Mar; 42(3):504-12. PubMed ID: 25512479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study.
    Pisaniello HL; Lester S; Gonzalez-Chica D; Stocks N; Longo M; Sharplin GR; Dal Grande E; Gill TK; Whittle SL; Hill CL
    Arthritis Res Ther; 2018 Jul; 20(1):143. PubMed ID: 29996922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rate of adherence to urate-lowering therapy and associated factors in Chinese gout patients: a cross-sectional study.
    Yin R; Cao H; Fu T; Zhang Q; Zhang L; Li L; Gu Z
    Rheumatol Int; 2017 Jul; 37(7):1187-1194. PubMed ID: 28551724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD).
    Scheepers LEJM; Burden AM; Arts ICW; Spaetgens B; Souverein P; de Vries F; Boonen A
    Rheumatology (Oxford); 2018 Sep; 57(9):1641-1650. PubMed ID: 29893941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study.
    Abhishek A; Jenkins W; La-Crette J; Fernandes G; Doherty M
    Rheumatology (Oxford); 2017 Apr; 56(4):529-533. PubMed ID: 28082620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel.
    Zandman-Goddard G; Amital H; Shamrayevsky N; Raz R; Shalev V; Chodick G
    Rheumatology (Oxford); 2013 Jun; 52(6):1126-31. PubMed ID: 23392592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial.
    Mikuls TR; Cheetham TC; Levy GD; Rashid N; Kerimian A; Low KJ; Coburn BW; Redden DT; Saag KG; Foster PJ; Chen L; Curtis JR
    Am J Med; 2019 Mar; 132(3):354-361. PubMed ID: 30503879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing adherence to allopurinol for gout: patients' perspectives.
    Spragg JCJ; Michael TJF; Aslani P; Coleshill MJ; Chan JS; Day RO; Stocker SL
    Br J Clin Pharmacol; 2023 Jul; 89(7):1978-1991. PubMed ID: 36607199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.